Guggenheim initiated coverage of Nautilus Biotechnology with a Buy rating and $6 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT:
- Nautilus Biotechnology assumed with a Hold from Buy at Jefferies
- Nautilus Biotechnology’s ESG Challenge: Navigating the Rising Tide of Corporate Responsibility Standards
- Nautilus Biotechnology Reports First Quarter 2024 Financial Results
- Nautilus Biotechnology reports Q1 EPS (15c) vs (12c) last year